Astrazeneca Pharma India Ltd Faces Bearish Momentum Amid Technical Downgrade

Price Movement and Market Context

The stock closed at ₹8,389.40 on 16 Mar 2026, down 2.44% from the previous close of ₹8,598.85. Intraday trading saw a high of ₹8,527.95 and a low of ₹8,300.00, reflecting increased volatility. Despite this decline, Astrazeneca Pharma remains well above its 52-week low of ₹6,501.60, though still significantly below its 52-week high of ₹10,653.05.

Comparatively, the stock has outperformed the Sensex over longer horizons, delivering a 10-year return of 566.14% against the Sensex’s 201.66%. However, recent short-term returns have been negative, with a 1-month return of -5.51% versus the Sensex’s -9.76%, and a year-to-date return of -6.89% compared to the Sensex’s -12.50%. This relative resilience is noteworthy but overshadowed by the current technical weakness.

Technical Trend Shift: From Mildly Bearish to Bearish

The technical trend for Astrazeneca Pharma has shifted from mildly bearish to outright bearish, signalling a deterioration in price momentum. This shift is corroborated by multiple technical indicators across different timeframes.

The Moving Average Convergence Divergence (MACD) indicator remains bearish on the weekly chart and mildly bearish on the monthly chart, indicating that the stock’s momentum is weakening but with some longer-term support. The Relative Strength Index (RSI), however, shows no clear signal on either weekly or monthly charts, suggesting the stock is neither oversold nor overbought at present, but momentum is lacking.

Bollinger Bands present a mixed picture: weekly readings are bearish, reflecting price pressure near the lower band, while monthly readings are mildly bullish, hinting at potential longer-term consolidation or support. The daily moving averages are firmly bearish, reinforcing the short-term downtrend.

Momentum Oscillators and Volume Analysis

The Know Sure Thing (KST) oscillator is bearish on the weekly timeframe and mildly bearish monthly, aligning with the MACD’s signals and confirming weakening momentum. Meanwhile, the On-Balance Volume (OBV) indicator is mildly bearish weekly but mildly bullish monthly, indicating that while recent volume trends have been negative, longer-term accumulation may still be occurring.

Dow Theory assessments are mildly bearish weekly but mildly bullish monthly, reflecting a divergence between short-term price action and longer-term trend expectations. This divergence suggests that while the stock faces immediate pressure, the broader trend may still hold some upside potential if support levels hold.

Mojo Score and Analyst Ratings

Astrazeneca Pharma India Ltd currently holds a Mojo Score of 37.0, categorised as a 'Sell' grade, downgraded from a previous 'Hold' rating on 2 Jan 2026. This downgrade reflects the deteriorating technical outlook and the increased risk profile of the stock. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility and sensitivity to market fluctuations.

Investors should note that the bearish technical signals, combined with the downgrade, suggest a cautious stance. The stock’s recent underperformance relative to the Sensex in the short term further supports this view.

Long-Term Performance Versus Market Benchmarks

Despite recent weakness, Astrazeneca Pharma’s long-term performance remains impressive. Over the past five years, the stock has returned 146.04%, significantly outperforming the Sensex’s 46.80%. Over three years, the outperformance is even more pronounced, with a 153.46% return versus the Sensex’s 28.03%. This strong historical performance underscores the company’s underlying business strength and sector positioning.

However, the current technical deterioration suggests that investors should monitor the stock closely for signs of a sustained reversal or further weakness before committing fresh capital.

Key Support and Resistance Levels

From a technical perspective, the stock’s immediate support lies near the ₹8,300 mark, close to today’s low. A breach below this level could open the door to retesting the 52-week low of ₹6,501.60. Resistance is observed near the recent intraday high of ₹8,527.95 and more significantly near the 52-week high of ₹10,653.05, which remains a distant target given current momentum.

Moving averages on the daily chart are bearish, indicating that the stock is trading below key averages such as the 50-day and 200-day moving averages, which often act as dynamic resistance levels in downtrends.

Investor Takeaway

In summary, Astrazeneca Pharma India Ltd is currently navigating a challenging technical environment. The shift from mildly bearish to bearish trends across multiple indicators, including MACD, moving averages, and KST, signals weakening price momentum. While longer-term indicators such as monthly Bollinger Bands and OBV suggest some underlying support, the short-term outlook remains cautious.

Investors should weigh the stock’s strong historical returns and sector fundamentals against the current technical signals and recent downgrade to a 'Sell' rating. Close monitoring of support levels and volume trends will be essential to identify any potential reversal or further downside risk.

Given the mixed signals and increased volatility, a prudent approach would be to await confirmation of trend stabilisation before increasing exposure. Those already invested may consider tightening stop-loss levels to protect gains amid the prevailing bearish momentum.

Comparative Performance Summary

To put the recent price action in perspective, Astrazeneca Pharma’s weekly return of -4.01% has outperformed the Sensex’s -5.52%, and its 1-month return of -5.51% is better than the Sensex’s -9.76%. Year-to-date, the stock’s decline of -6.89% is less severe than the Sensex’s -12.50%, indicating relative resilience despite the bearish technical backdrop.

Over longer periods, the stock’s outperformance is even more pronounced, with a 10-year return of 566.14% compared to the Sensex’s 201.66%. This highlights the company’s capacity for sustained growth, although recent technical deterioration warrants caution.

Conclusion

Astrazeneca Pharma India Ltd’s technical indicators collectively point to a bearish momentum phase, with multiple oscillators and moving averages confirming weakening price strength. The downgrade to a 'Sell' Mojo Grade reinforces the need for caution. While the stock’s long-term fundamentals and historical returns remain robust, the current technical environment suggests investors should adopt a measured stance and monitor for signs of recovery before committing additional capital.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →